Clinical cancer research : an official journal of the American Association for Cancer Research
Journal
Overview
publication venue for
-
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
2020
-
Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma.
2018
-
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
2024
-
A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer.
2024
-
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial.
2024
-
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
2024
-
MEK inhibitors lead to PDGFR pathway upregulation and sensitize tumors to RAF dimer inhibitors in NF1-deficient malignant peripheral nerve sheath tumor (MPNST).
2024
-
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer..
30.
2024
-
Multiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma..
30.
2024
-
A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.
2024
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
2024
-
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer..
30.
2024
-
A Phase II study assessing Long-Term Response to Ibrutinib Monotherapy in recurrent or refractory CNS Lymphoma.
2024
-
Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
2024
-
Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets.
2024
-
A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: the Hidden-Genome Classifier.
2024
-
Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.
2024
-
KLRG1, Another Opportunity for a Breakthrough in MTCL..
30.
2024
-
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
2024
-
Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
2024
-
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
2024
-
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11.
2024
-
Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.
2024
-
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
2024
-
Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable.
2023
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
2023
-
Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma.
2023
-
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer..
29.
2023
-
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder..
29.
2023
-
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma..
29.
2023
-
Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era..
29.
2023
-
Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence.
2023
-
Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
2023
-
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer..
29.
2023
-
Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma.
2023
-
Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience.
2023
-
De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways..
29.
2023
-
Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
2023
-
SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression.
2023
-
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer..
29.
2023
-
ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
2023
-
The Impact of Germline Alterations in Appendiceal Adenocarcinoma..
29.
2023
-
Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
2023
-
Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis.
2023
-
Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer.
2023
-
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma..
29.
2023
-
The Immunogenomic Landscape of Neuroendocrine Prostate Cancer.
2023
-
Clonal Hematopoiesis in Young Women Treated for Breast Cancer.
2023
-
Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy..
29.
2023
-
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma..
29.
2023
-
Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
2023
-
Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer.
2023
-
PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer.
2023
-
Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases..
29.
2023
-
High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer..
29.
2023
-
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects..
29.
2023
-
Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation..
29.
2023
-
Crizotinib has Preclinical Efficacy in Philadelphia-negative Myeloproliferative Neoplasms.
2022
-
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention..
28.
2022
-
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors..
28.
2022
-
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts..
28.
2022
-
MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma..
28.
2022
-
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles..
28.
2022
-
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade..
28.
2022
-
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer..
28.
2022
-
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
2022
-
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
2022
-
Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma..
28.
2022
-
The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma..
28.
2022
-
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program..
28.
2022
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials..
28.
2022
-
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab..
28.
2022
-
Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study.
2022
-
A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma..
28.
2022
-
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity..
28.
2022
-
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis..
28.
2022
-
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody..
28.
2022
-
Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma..
28.
2022
-
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial..
28.
2022
-
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer..
28.
2022
-
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST).
2022
-
Bone marrow surveillance of pediatric cancer survivors identifies clones that predict therapy-related leukemia.
2022
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study..
27.
2021
-
Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe..
27.
2021
-
Genome-derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care.
2021
-
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop..
27.
2021
-
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial..
27.
2021
-
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer..
27.
2021
-
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer..
27.
2021
-
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer..
27.
2021
-
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia..
27.
2021
-
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients..
27.
2021
-
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial..
27.
2021
-
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors..
27.
2021
-
Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection..
27.
2021
-
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer..
27.
2021
-
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes..
27.
2021
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide..
27.
2021
-
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways..
27.
2021
-
Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms..
27.
2021
-
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response..
27.
2021
-
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study..
27.
2021
-
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations..
27.
2021
-
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions..
27.
2021
-
KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma..
27.
2021
-
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer..
27.
2021
-
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas..
27.
2021
-
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer..
27.
2021
-
Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET..
27.
2021
-
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer..
27.
2021
-
The State of Melanoma: Emergent Challenges and Opportunities..
27.
2021
-
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas..
27.
2020
-
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer..
27.
2020
-
Genomic Characterization of de novo Metastatic Breast Cancer..
27.
2020
-
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor..
27.
2020
-
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma..
27.
2020
-
Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma..
27.
2020
-
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance..
27.
2020
-
Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia..
27.
2020
-
Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer..
27.
2020
-
Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors..
26.
2020
-
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation..
26.
2020
-
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer..
26.
2020
-
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study..
26.
2020
-
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome..
26.
2020
-
Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics..
26.
2020
-
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer..
26.
2020
-
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors..
26.
2020
-
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer..
26.
2020
-
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome..
26.
2020
-
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)..
26.
2020
-
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection..
26.
2020
-
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer..
26.
2020
-
Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer..
26.
2020
-
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer..
26.
2020
-
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing..
26.
2020
-
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer..
26.
2020
-
Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer..
26.
2020
-
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression..
26.
2020
-
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer..
26.
2020
-
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study..
26.
2020
-
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer..
26.
2020
-
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models..
26.
2020
-
Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients..
26.
2020
-
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions..
26.
2020
-
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer..
26.
2020
-
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial..
26.
2020
-
Targeted Brain Tumor Radiotherapy Using an Auger Emitter..
26.
2020
-
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype..
26.
2020
-
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC..
26.
2020
-
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors..
26.
2020
-
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer..
26.
2020
-
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers..
26.
2020
-
Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival..
26.
2020
-
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations..
26.
2019
-
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis..
26.
2019
-
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies..
26.
2019
-
Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer..
26.
2019
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma..
26.
2019
-
Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer..
26.
2019
-
Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma..
26.
2019
-
Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability..
26.
2019
-
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma..
26.
2019
-
Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma..
26.
2019
-
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer..
25.
2019
-
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation..
25.
2019
-
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer..
25.
2019
-
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model..
26.
2019
-
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study..
25.
2019
-
Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach..
25.
2019
-
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors..
25.
2019
-
Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma..
25.
2019
-
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer..
25.
2019
-
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan..
25.
2019
-
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer..
25.
2019
-
Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer..
25.
2019
-
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations..
25.
2019
-
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas..
25.
2019
-
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report..
25.
2019
-
Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo..
25.
2019
-
Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations..
25.
2019
-
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer..
25.
2019
-
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden..
25.
2019
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice..
25.
2019
-
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells..
25.
2019
-
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas..
25.
2019
-
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab..
25.
2019
-
Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer..
25.
2019
-
Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination..
25.
2019
-
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma..
25.
2019
-
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial..
25.
2019
-
Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702)..
25.
2019
-
Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?.
25.
2019
-
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies..
24.
2019
-
Epigenetic Silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-Positive Prostate Cancer..
25.
2018
-
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance..
25.
2018
-
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers..
25.
2018
-
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism..
25.
2018
-
A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers..
25.
2018
-
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma..
25.
2018
-
Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging..
25.
2018
-
Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations..
25.
2018
-
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis..
25.
2018
-
Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer..
25.
2018
-
Retraction: NRH:Quinone Oxidoreductase 2-Deficient Mice Are Highly Susceptible to Radiation-induced B-Cell Lymphomas..
24.
2018
-
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies..
25.
2018
-
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer..
25.
2018
-
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma..
25.
2018
-
Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma..
25.
2018
-
PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial..
25.
2018
-
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer..
25.
2018
-
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY..
25.
2018
-
Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer..
25.
2018
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers..
25.
2018
-
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer..
25.
2018
-
Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma..
25.
2018
-
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors..
25.
2018
-
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact..
24.
2018
-
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan..
24.
2018
-
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma..
24.
2018
-
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial..
24.
2018
-
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma..
24.
2018
-
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer..
24.
2018
-
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity..
24.
2018
-
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers..
25.
2018
-
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration..
24.
2018
-
Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling..
24.
2018
-
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer..
25.
2018
-
Mast Cell Activation and KSHV Infection in Kaposi Sarcoma..
24.
2018
-
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells..
24.
2018
-
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts..
24.
2018
-
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy..
24.
2018
-
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays..
24.
2018
-
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention..
24.
2018
-
Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers..
24.
2018
-
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas..
24.
2018
-
TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer..
24.
2018
-
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib..
24.
2018
-
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study..
24.
2018
-
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab..
24.
2018
-
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer..
24.
2018
-
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy..
23.
2018
-
Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib..
24.
2018
-
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance..
24.
2018
-
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer..
24.
2018
-
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer..
24.
2018
-
Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts..
24.
2018
-
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer..
24.
2018
-
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study..
24.
2018
-
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers..
24.
2018
-
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations..
24.
2018
-
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP..
24.
2018
-
Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma..
24.
2018
-
Personalized RNA Medicine for Pancreatic Cancer..
24.
2018
-
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors..
24.
2017
-
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer..
24.
2017
-
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis..
24.
2017
-
RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition..
24.
2017
-
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer..
24.
2017
-
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma..
24.
2017
-
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors..
24.
2017
-
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors..
23.
2017
-
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma..
23.
2017
-
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations..
23.
2017
-
Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors..
24.
2017
-
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide..
23.
2017
-
Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research..
24.
2017
-
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer..
23.
2017
-
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models..
23.
2017
-
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype..
23.
2017
-
Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells..
23.
2017
-
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan..
23.
2017
-
Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence..
23.
2017
-
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers..
23.
2017
-
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer..
23.
2017
-
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma..
23.
2017
-
Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin..
23.
2017
-
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer..
23.
2017
-
Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial..
23.
2017
-
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer..
23.
2017
-
In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The φ-Index..
23.
2017
-
Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer..
23.
2017
-
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083..
23.
2017
-
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases..
23.
2017
-
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy..
23.
2017
-
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma..
23.
2017
-
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer..
23.
2017
-
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone..
23.
2017
-
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma..
23.
2017
-
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas..
23.
2017
-
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma..
23.
2017
-
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma..
23.
2017
-
Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells..
23.
2016
-
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity..
23.
2016
-
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma..
23.
2016
-
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations..
23.
2016
-
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab..
23.
2016
-
Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin..
23.
2016
-
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib..
23.
2016
-
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study..
23.
2016
-
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial..
23.
2016
-
Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required..
23.
2016
-
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins..
23.
2016
-
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response..
23.
2016
-
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases..
23.
2016
-
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma..
22.
2016
-
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody..
23.
2016
-
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors..
23.
2016
-
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy..
23.
2016
-
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer..
23.
2016
-
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population..
23.
2016
-
Prognostic Utility of a New mRNA Expression Signature of Gleason Score..
23.
2016
-
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling..
22.
2016
-
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer..
23.
2016
-
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer..
23.
2016
-
Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer..
23.
2016
-
An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer..
22.
2016
-
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma..
22.
2016
-
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab..
22.
2016
-
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab..
22.
2016
-
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial..
22.
2016
-
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer..
23.
2016
-
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer..
22.
2016
-
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life..
22.
2016
-
Precision Medicine for Diffuse Large B-cell Lymphoma..
22.
2016
-
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets..
22.
2016
-
The Genomic Landscape of Male Breast Cancers..
22.
2016
-
Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research..
22.
2016
-
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)..
22.
2016
-
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer..
22.
2016
-
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients..
22.
2016
-
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors..
22.
2016
-
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab..
22.
2016
-
Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma..
22.
2016
-
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma..
22.
2016
-
A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases..
22.
2016
-
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics..
22.
2016
-
The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis..
22.
2016
-
Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma
2016
-
Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer..
22.
2015
-
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study..
21.
2015
-
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer..
22.
2015
-
Identification of a Novel Pathogenic Germline KDR Variant in Melanoma..
22.
2015
-
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations..
22.
2015
-
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors..
22.
2015
-
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib..
22.
2015
-
Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer..
22.
2015
-
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer..
22.
2015
-
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas..
22.
2015
-
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy..
22.
2015
-
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma..
22.
2015
-
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses..
22.
2015
-
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors..
22.
2015
-
Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer..
22.
2015
-
A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation..
22.
2015
-
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities..
22.
2015
-
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors..
21.
2015
-
Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma..
21.
2015
-
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer..
21.
2015
-
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial..
21.
2015
-
Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models..
21.
2015
-
A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis..
21.
2015
-
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors..
21.
2015
-
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer..
21.
2015
-
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors..
21.
2015
-
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients..
21.
2015
-
Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate..
21.
2015
-
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019..
21.
2015
-
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer..
21.
2015
-
Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer..
21.
2015
-
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms..
21.
2015
-
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition..
21.
2015
-
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs..
21.
2015
-
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate..
21.
2015
-
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients..
21.
2015
-
Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology..
21.
2015
-
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches..
21.
2015
-
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
2015
-
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial..
21.
2014
-
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors..
21.
2014
-
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors..
21.
2014
-
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers..
21.
2014
-
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking..
21.
2014
-
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer..
21.
2014
-
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors..
21.
2014
-
Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma..
20.
2014
-
Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function..
20.
2014
-
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study..
20.
2014
-
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma..
20.
2014
-
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer..
20.
2014
-
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma..
20.
2014
-
Evidence for molecular differences in prostate cancer between African American and Caucasian men..
20.
2014
-
Activating FGFR2-RAS-BRAF mutations in ameloblastoma..
20.
2014
-
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)..
20.
2014
-
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance..
20.
2014
-
Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy..
20.
2014
-
Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score..
20.
2014
-
Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein..
20.
2014
-
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors..
20.
2014
-
Blocking and randomization to improve molecular biomarker discovery..
20.
2014
-
Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity..
20.
2014
-
Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs..
20.
2014
-
SPINK1 protein expression and prostate cancer progression..
20.
2014
-
Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment..
20.
2014
-
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma..
20.
2014
-
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy..
20.
2014
-
Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor..
20.
2014
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries..
20.
2014
-
Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG..
20.
2014
-
Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission..
20.
2014
-
Detection of cancer DNA in plasma of patients with early-stage breast cancer..
20.
2014
-
High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma..
20.
2014
-
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma..
20.
2014
-
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer..
20.
2014
-
DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes..
20.
2013
-
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma..
20.
2013
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial..
20.
2013
-
The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo..
19.
2013
-
Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer..
19.
2013
-
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein..
19.
2013
-
AACR Cancer Progress Report 2013..
19.
2013
-
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803..
19.
2013
-
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response..
19.
2013
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer..
19.
2013
-
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class..
19.
2013
-
Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors..
19.
2013
-
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)..
19.
2013
-
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer..
19.
2013
-
Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer..
19.
2013
-
Developing standards for breakthrough therapy designation in oncology..
19.
2013
-
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer..
19.
2013
-
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease..
19.
2013
-
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network..
19.
2013
-
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors..
19.
2013
-
Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer..
19.
2013
-
Characteristics of lung cancers harboring NRAS mutations..
19.
2013
-
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers..
19.
2013
-
Agonist antibodies to TNFR molecules that costimulate T and NK cells..
19.
2013
-
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types..
19.
2013
-
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma..
19.
2013
-
Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors..
19.
2013
-
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma..
19.
2013
-
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets..
19.
2013
-
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors..
19.
2013
-
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization..
19.
2013
-
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer..
19.
2013
-
Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients..
19.
2013
-
Personalized chemotherapy profiling using cancer cell lines from selectable mice..
19.
2013
-
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer..
18.
2012
-
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions..
18.
2012
-
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer..
18.
2012
-
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission..
18.
2012
-
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients..
18.
2012
-
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers..
18.
2012
-
AACR Cancer Progress Report 2012..
18.
2012
-
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma..
18.
2012
-
Scatter spectroscopic imaging distinguishes between breast pathologies in tissues relevant to surgical margin assessment..
18.
2012
-
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo..
18.
2012
-
EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors..
18.
2012
-
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment..
18.
2012
-
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials..
18.
2012
-
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors..
18.
2012
-
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer..
18.
2012
-
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma..
18.
2012
-
Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6..
18.
2012
-
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas..
18.
2012
-
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations..
18.
2012
-
A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival..
18.
2012
-
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors..
18.
2012
-
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer..
18.
2012
-
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma..
18.
2012
-
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood..
18.
2012
-
IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma..
18.
2012
-
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial..
18.
2012
-
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors..
18.
2012
-
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients..
18.
2012
-
A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration..
18.
2012
-
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth..
18.
2012
-
18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy..
18.
2012
-
A three-gene expression signature model for risk stratification of patients with neuroblastoma..
18.
2012
-
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia..
18.
2012
-
Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability..
18.
2012
-
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations..
18.
2012
-
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer..
18.
2012
-
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker..
18.
2012
-
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma..
18.
2011
-
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models..
18.
2011
-
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803..
18.
2011
-
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer..
18.
2011
-
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo..
17.
2011
-
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy..
17.
2011
-
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas..
17.
2011
-
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design..
17.
2011
-
Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype..
17.
2011
-
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib..
17.
2011
-
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group..
17.
2011
-
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes..
17.
2011
-
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer..
17.
2011
-
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905)..
17.
2011
-
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept..
17.
2011
-
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin..
17.
2011
-
Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens..
17.
2011
-
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab..
17.
2011
-
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene..
17.
2011
-
Activity of Sorafenib against desmoid tumor/deep fibromatosis..
17.
2011
-
Therapeutic implications of the emerging molecular biology of uveal melanoma..
17.
2011
-
Molecular classification of gastric cancer: a new paradigm..
17.
2011
-
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts..
17.
2011
-
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing..
17.
2011
-
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors..
17.
2011
-
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib..
17.
2011
-
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo..
17.
2011
-
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer..
17.
2011
-
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma..
17.
2011
-
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence..
17.
2011
-
Androgen receptor expression and breast cancer survival in postmenopausal women..
17.
2011
-
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features..
17.
2011
-
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding..
17.
2011
-
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors..
17.
2011
-
Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas..
17.
2011
-
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors..
17.
2011
-
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib..
17.
2011
-
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay..
17.
2011
-
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging..
17.
2011
-
Role and relevance of TrkB mutations and expression in non-small cell lung cancer..
17.
2011
-
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations..
17.
2011
-
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib..
17.
2011
-
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition..
17.
2011
-
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance..
16.
2010
-
The impact of insurance on access to cancer clinical trials at a comprehensive cancer center..
16.
2010
-
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation..
17.
2010
-
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer..
17.
2010
-
Benign mesenchymal stromal cells in human sarcomas..
16.
2010
-
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation..
17.
2010
-
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer..
16.
2010
-
Portable filter-based microdevice for detection and characterization of circulating tumor cells..
16.
2010
-
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia..
16.
2010
-
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study..
16.
2010
-
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group..
16.
2010
-
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial..
16.
2010
-
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder..
16.
2010
-
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection..
16.
2010
-
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen..
16.
2010
-
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F..
16.
2010
-
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development..
16.
2010
-
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial..
16.
2010
-
Susceptibility loci associated with prostate cancer progression and mortality..
16.
2010
-
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor..
16.
2010
-
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam..
16.
2010
-
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors..
16.
2010
-
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494..
16.
2010
-
In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts..
16.
2010
-
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer..
16.
2010
-
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers..
16.
2010
-
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer..
16.
2010
-
A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies..
16.
2010
-
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry..
16.
2010
-
Melanoma MicroRNA signature predicts post-recurrence survival..
16.
2010
-
Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge..
16.
2010
-
Frequent downregulation of miR-34 family in human ovarian cancers..
16.
2010
-
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma..
16.
2010
-
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib..
16.
2010
-
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report..
16.
2010
-
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation..
16.
2010
-
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes..
16.
2010
-
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors..
16.
2009
-
Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer..
16.
2009
-
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria..
15.
2009
-
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma..
15.
2009
-
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803..
15.
2009
-
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors..
15.
2009
-
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer..
15.
2009
-
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study..
15.
2009
-
Activation of host wound responses in breast cancer microenvironment..
15.
2009
-
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas..
15.
2009
-
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance..
15.
2009
-
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells..
15.
2009
-
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer..
15.
2009
-
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer..
15.
2009
-
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival..
15.
2009
-
Translocator protein blockade reduces prostate tumor growth..
15.
2009
-
Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer..
15.
2009
-
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure..
15.
2009
-
Interaction of molecular markers and physical activity on mortality in patients with colon cancer..
15.
2009
-
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody..
15.
2009
-
Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers..
15.
2009
-
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials..
15.
2009
-
PIK3CA mutation associates with improved outcome in breast cancer..
15.
2009
-
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma..
15.
2009
-
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population..
15.
2009
-
Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training..
15.
2009
-
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States..
15.
2009
-
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer..
15.
2009
-
GAB2 amplifications refine molecular classification of melanoma..
15.
2009
-
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma..
15.
2009
-
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene..
15.
2009
-
Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles..
15.
2009
-
A phase I trial of enzastaurin in patients with recurrent gliomas..
15.
2009
-
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies..
15.
2009
-
Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology..
15.
2009
-
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer..
15.
2009
-
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas..
15.
2009
-
Phosphorylated 4E-BP1 is associated with poor survival in melanoma..
15.
2009
-
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma..
15.
2009
-
Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination..
15.
2009
-
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer..
15.
2009
-
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer..
15.
2009
-
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells..
15.
2009
-
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803..
15.
2009
-
NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomas..
15.
2009
-
A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma..
15.
2009
-
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck..
15.
2009
-
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma..
15.
2009
-
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade..
15.
2009
-
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer..
15.
2009
-
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors..
15.
2009
-
A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients..
14.
2008
-
Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma..
14.
2008
-
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma..
14.
2008
-
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer..
14.
2008
-
Cancer-related axonogenesis and neurogenesis in prostate cancer..
14.
2008
-
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer..
14.
2008
-
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt..
14.
2008
-
Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer..
14.
2008
-
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers..
14.
2008
-
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib..
14.
2008
-
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma..
14.
2008
-
SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2..
14.
2008
-
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors..
14.
2008
-
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer..
14.
2008
-
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer..
14.
2008
-
CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer..
14.
2008
-
Deletions of CDKN2C in multiple myeloma: biological and clinical implications..
14.
2008
-
Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients..
14.
2008
-
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma..
14.
2008
-
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival..
14.
2008
-
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo..
14.
2008
-
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer..
14.
2008
-
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth..
14.
2008
-
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer..
14.
2008
-
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183..
14.
2008
-
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing..
14.
2008
-
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers..
14.
2008
-
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications..
14.
2008
-
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer..
14.
2008
-
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma..
14.
2008
-
Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy..
14.
2008
-
Molecular characterization of pediatric gastrointestinal stromal tumors..
14.
2008
-
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission..
14.
2008
-
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma..
14.
2008
-
Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging..
14.
2008
-
Prognostic value of body mass index in locally advanced breast cancer..
14.
2008
-
Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy..
14.
2008
-
Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer..
14.
2008
-
Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer..
14.
2008
-
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas..
14.
2008
-
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes..
14.
2008
-
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples..
14.
2008
-
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers..
14.
2008
-
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer..
13.
2007
-
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma..
13.
2007
-
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors..
13.
2007
-
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer..
13.
2007
-
Novel markers of subclinical disease for Ewing family tumors from gene expression profiling..
13.
2007
-
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study..
13.
2007
-
Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion..
13.
2007
-
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response..
13.
2007
-
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine..
13.
2007
-
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma..
13.
2007
-
Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma..
13.
2007
-
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors..
13.
2007
-
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases..
13.
2007
-
Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer..
13.
2007
-
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts..
13.
2007
-
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus..
13.
2007
-
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?.
13.
2007
-
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor..
13.
2007
-
Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder..
13.
2007
-
Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors..
13.
2007
-
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells..
13.
2007
-
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy..
13.
2007
-
BRCA mutations in women with ductal carcinoma in situ..
13.
2007
-
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma..
13.
2007
-
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer..
13.
2007
-
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer..
13.
2007
-
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183..
13.
2007
-
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors..
13.
2007
-
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes..
13.
2007
-
In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors..
13.
2007
-
A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer..
13.
2007
-
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway..
13.
2007
-
Disruption of endothelial cell interactions with the novel HU177 cryptic collagen epitope inhibits angiogenesis..
13.
2007
-
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21..
13.
2007
-
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors..
13.
2007
-
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor..
13.
2007
-
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors..
13.
2007
-
Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2..
13.
2007
-
The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate..
13.
2007
-
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer..
13.
2007
-
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer..
13.
2007
-
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors..
13.
2007
-
Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors..
13.
2007
-
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer..
13.
2007
-
Relaxin promotes prostate cancer progression..
13.
2007
-
The association between measures of progression and survival in castrate-metastatic prostate cancer..
13.
2007
-
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs..
13.
2007
-
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system..
13.
2007
-
Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer..
13.
2007
-
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer..
13.
2007
-
Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors..
13.
2007
-
Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease..
12.
2006
-
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors..
12.
2006
-
Rapid androgen cycling as treatment for patients with prostate cancer..
12.
2006
-
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma..
12.
2006
-
Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes..
12.
2006
-
Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma..
12.
2006
-
Nomograms provide improved accuracy for predicting survival after radical cystectomy..
12.
2006
-
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation..
12.
2006
-
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer..
12.
2006
-
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors..
12.
2006
-
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors..
12.
2006
-
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus..
12.
2006
-
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study..
12.
2006
-
GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1..
12.
2006
-
Pharmacokinetics and toxicity of weekly docetaxel in older patients..
12.
2006
-
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer..
12.
2006
-
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma..
12.
2006
-
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma..
12.
2006
-
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors..
12.
2006
-
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas..
12.
2006
-
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains..
12.
2006
-
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma..
12.
2006
-
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer..
12.
2006
-
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy..
12.
2006
-
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08..
12.
2006
-
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort..
12.
2006
-
An in vivo platform for translational drug development in pancreatic cancer..
12.
2006
-
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice..
12.
2006
-
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas..
12.
2006
-
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors..
12.
2006
-
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival..
12.
2006
-
c-Met ectodomain shedding rate correlates with malignant potential..
12.
2006
-
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib..
12.
2006
-
Novel blood biomarkers of human urinary bladder cancer..
12.
2006
-
Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases..
12.
2006
-
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival..
12.
2006
-
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue..
12.
2006
-
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study..
12.
2006
-
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo..
12.
2006
-
Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity..
12.
2006
-
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer..
12.
2006
-
Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies..
12.
2006
-
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening..
12.
2006
-
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib..
12.
2006
-
Stress hormone-mediated invasion of ovarian cancer cells..
12.
2006
-
Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer..
12.
2006
-
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity..
12.
2006
-
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder..
11.
2005
-
Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens..
11.
2005
-
Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96..
11.
2005
-
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy..
11.
2005
-
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes..
11.
2005
-
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent..
11.
2005
-
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer..
11.
2005
-
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer..
11.
2005
-
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles..
11.
2005
-
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01..
11.
2005
-
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer..
11.
2005
-
Morphologic instability and cancer invasion..
11.
2005
-
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia..
11.
2005
-
Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts..
11.
2005
-
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer..
11.
2005
-
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma..
11.
2005
-
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer..
11.
2005
-
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies..
11.
2005
-
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon..
11.
2005
-
Breast cancer molecular subtypes respond differently to preoperative chemotherapy..
11.
2005
-
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer..
11.
2005
-
PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation..
11.
2005
-
Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy..
11.
2005
-
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy..
11.
2005
-
Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma..
11.
2005
-
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation..
11.
2005
-
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer..
11.
2005
-
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol..
11.
2005
-
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma..
11.
2005
-
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes..
11.
2005
-
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy..
11.
2005
-
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy..
11.
2005
-
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy..
11.
2005
-
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model..
11.
2005
-
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma..
11.
2005
-
Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma..
11.
2005
-
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer..
11.
2005
-
Reg IV: a promising marker of hormone refractory metastatic prostate cancer..
11.
2005
-
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel..
11.
2005
-
An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle..
11.
2005
-
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene..
11.
2005
-
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma..
11.
2005
-
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer..
11.
2005
-
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma..
11.
2005
-
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma..
11.
2005
-
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity..
10.
2004
-
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer..
10.
2004
-
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1..
10.
2004
-
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity..
10.
2004
-
The radioisotope contributes significantly to the activity of radioimmunotherapy..
10.
2004
-
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia..
10.
2004
-
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients..
10.
2004
-
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study..
10.
2004
-
In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity..
10.
2004
-
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2..
10.
2004
-
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties..
10.
2004
-
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence..
10.
2004
-
NY-ESO-1 expression and immunogenicity in esophageal cancer..
10.
2004
-
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities..
10.
2004
-
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin..
10.
2004
-
p53 expression as a prognostic marker in inflammatory breast cancer..
10.
2004
-
Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung..
10.
2004
-
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer..
10.
2004
-
The role of hyperthermia in regional alkylating agent chemotherapy..
10.
2004
-
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results..
10.
2004
-
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients..
10.
2004
-
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor..
10.
2004
-
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside..
10.
2004
-
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression..
10.
2004
-
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12..
10.
2004
-
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer..
10.
2004
-
Neutral endopeptidase protein expression and prognosis in localized prostate cancer..
10.
2004
-
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments..
10.
2004
-
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors..
10.
2004
-
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site..
10.
2004
-
Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study..
10.
2004
-
Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer..
10.
2004
-
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis..
10.
2004
-
BRCA mutations and risk of prostate cancer in Ashkenazi Jews..
10.
2004
-
Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity..
10.
2004
-
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial..
10.
2004
-
Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin..
10.
2004
-
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy..
10.
2004
-
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)..
10.
2004
-
Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression..
10.
2004
-
Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin..
10.
2004
-
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)..
10.
2004
-
Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia..
10.
2004
-
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis..
10.
2004
-
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes..
10.
2004
-
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin..
10.
2004
-
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma..
10.
2004
-
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase..
10.
2004
-
Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12..
10.
2004
-
Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice..
10.
2004
-
Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer..
10.
2004
-
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro..
9.
2003
-
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer..
9.
2003
-
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21..
9.
2003
-
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies..
9.
2003
-
Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney..
9.
2003
-
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer..
9.
2003
-
Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging..
9.
2003
-
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling..
9.
2003
-
A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer..
9.
2003
-
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties..
9.
2003
-
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously..
9.
2003
-
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer..
9.
2003
-
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index..
9.
2003
-
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors..
9.
2003
-
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients..
9.
2003
-
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer..
9.
2003
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors..
9.
2003
-
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients..
9.
2003
-
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer..
9.
2003
-
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer..
9.
2003
-
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas..
9.
2003
-
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways..
9.
2003
-
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue..
9.
2003
-
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer..
9.
2003
-
Classification of follicular thyroid tumors by molecular signature: results of gene profiling..
9.
2003
-
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants..
9.
2003
-
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial..
9.
2003
-
Phase I study of anticolon cancer humanized antibody A33..
9.
2003
-
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer..
9.
2003
-
High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer..
9.
2003
-
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples..
9.
2003
-
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer..
9.
2003
-
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer..
9.
2003
-
P7 antigen expression in human breast cancer..
9.
2003
-
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors..
8.
2002
-
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations..
8.
2002
-
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers..
8.
2002
-
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer..
8.
2002
-
Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis..
8.
2002
-
Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors..
8.
2002
-
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women..
8.
2002
-
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer..
8.
2002
-
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies..
8.
2002
-
Quantifying the amount of variation in survival explained by prostate-specific antigen..
8.
2002
-
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies..
8.
2002
-
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia..
8.
2002
-
Synergistic activation of the androgen receptor by bombesin and low-dose androgen..
8.
2002
-
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts..
8.
2002
-
Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses..
8.
2002
-
Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma..
8.
2002
-
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants..
8.
2002
-
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer..
8.
2002
-
Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma..
8.
2002
-
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer..
8.
2002
-
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel..
8.
2002
-
Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines..
8.
2002
-
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study..
8.
2002
-
Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460..
8.
2002
-
Picking the winners in a sea of plenty..
8.
2002
-
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development..
8.
2002
-
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies..
8.
2002
-
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods..
8.
2002
-
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts..
7.
2001
-
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma..
7.
2001
-
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer..
7.
2001
-
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks..
7.
2001
-
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases..
7.
2001
-
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy..
7.
2001
-
Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums..
7.
2001
-
Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma..
7.
2001
-
The T cell death knell: immune-mediated tumor death in renal cell carcinoma..
7.
2001
-
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662..
7.
2001
-
Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents..
7.
2001
-
Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study..
7.
2001
-
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer..
7.
2001
-
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer..
7.
2001
-
Biological behavior of human breast cancer micrometastases..
7.
2001
-
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients..
7.
2001
-
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001..
7.
2001
-
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients..
7.
2001
-
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR..
7.
2001
-
Collocation of androgen receptor gene mutations in prostate cancer..
7.
2001
-
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer..
7.
2001
-
Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma..
7.
2001
-
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer..
7.
2001
-
Reduction of paclitaxel-induced peripheral neuropathy with glutamine..
7.
2001
-
Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells..
7.
2001
-
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase..
7.
2001
-
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin..
7.
2001
-
Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations..
7.
2001
-
Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments..
6.
2000
-
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase..
6.
2000
-
Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle..
6.
2000
-
Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma..
6.
2000
-
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment..
6.
2000
-
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients..
6.
2000
-
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin..
6.
2000
-
Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma..
6.
2000
-
Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development..
6.
2000
-
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo..
6.
2000
-
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate..
6.
2000
-
Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma..
6.
2000
-
Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements..
6.
2000
-
Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3..
6.
2000
-
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)..
6.
2000
-
Methylation of the neutral endopeptidase gene promoter in human prostate cancers..
6.
2000
-
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone..
6.
2000
-
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21..
6.
2000
-
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow..
6.
2000
-
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer..
6.
2000
-
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study..
6.
2000
-
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer..
6.
2000
-
Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia..
6.
2000
-
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients..
6.
2000
-
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway..
6.
2000
-
Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group..
5.
1999
-
Different patterns of angiogenesis in sarcomas and carcinomas..
5.
1999
-
Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer..
5.
1999
-
Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model..
5.
1999
-
Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth..
5.
1999
-
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia..
5.
1999
-
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer..
5.
1999
-
Prostate-specific membrane antigen is produced in tumor-associated neovasculature..
5.
1999
-
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs..
5.
1999
-
Association between molecular detection of GAGE and survival in patients with malignant melanoma: a retrospective cohort study..
5.
1999
-
Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer..
5.
1999
-
Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia..
5.
1999
-
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression..
5.
1999
-
Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas..
5.
1999
-
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a..
5.
1999
-
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin..
5.
1999
-
Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer..
5.
1999
-
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma..
5.
1999
-
Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer..
5.
1999
-
Mechanisms of methotrexate resistance in osteosarcoma..
5.
1999
-
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer..
5.
1999
-
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies..
5.
1999
-
Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice..
4.
1998
-
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies..
4.
1998
-
Antileukemia activity of a natural killer cell line against human leukemias..
4.
1998
-
Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers..
4.
1998
-
Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells..
4.
1998
-
Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma..
4.
1998
-
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma..
4.
1998
-
Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas..
4.
1998
-
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma..
4.
1998
-
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner..
4.
1998
-
Elevated expression of caveolin is associated with prostate and breast cancer..
4.
1998
-
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity..
4.
1998
-
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index..
4.
1998
-
Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia..
4.
1998
-
p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer..
4.
1998
-
In vivo native cellular fluorescence and histological characteristics of head and neck cancer..
4.
1998
-
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma..
4.
1998
-
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer..
4.
1998
-
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers..
4.
1998
-
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma..
4.
1998
-
Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma..
4.
1998
-
Antitumor activity of actinonin in vitro and in vivo..
4.
1998
-
Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer..
3.
1997
-
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors..
3.
1997
-
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status..
3.
1997
-
Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma..
3.
1997
-
Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells..
3.
1997
-
Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer..
3.
1997
-
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells..
3.
1997
-
Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer..
3.
1997
-
Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer..
3.
1997
-
Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases..
3.
1997
-
Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma..
3.
1997
-
A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin..
3.
1997
-
Alterations affecting the p53 control pathway in bilharzial-related bladder cancer..
3.
1997
-
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi..
3.
1997
-
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression..
3.
1997
-
A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas..
3.
1997
-
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas..
3.
1997
-
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma..
3.
1997
-
Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells..
3.
1997
-
K-ras mutation in adenomas and carcinomas of the ampulla of vater..
3.
1997
-
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer..
2.
1996
-
Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma..
2.
1996
-
Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid..
2.
1996
-
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant..
2.
1996
-
Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study..
2.
1996
-
Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen..
2.
1996
-
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid..
2.
1996
-
Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression..
2.
1996
-
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma..
2.
1996
-
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines..
2.
1996
-
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma..
1.
1995
-
Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma..
1.
1995
-
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer..
1.
1995
-
Association of p53 mutations with metastatic prostate cancer..
1.
1995
-
Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model..
1.
1995
-
Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma..
1.
1995
-
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms..
1.
1995
-
Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia..
1.
1995
-
MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival
-
MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival
-
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?.
26.
2020
-
Clinical Significance of AR-V567es in Prostate Cancer-Response..
25.
2019
-
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology..
21.
2015
-
RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Response..
21.
2015
-
Pharmacogenomic modeling in pancreatic cancer—response..
21.
2015
-
Inclusion of patients with brain metastases in phase I trials: an unmet need..
17.
2011
-
Telomeres: the long and short of developing non-Hodgkin lymphoma..
15.
2009
-
Prediction of cancer relapse after prostatectomy: use the postoperative nomogram..
15.
2009
-
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer..
13.
2007
-
Correspondence re: C. G. Ferreira et al., Apoptosis: target of cancer therapy. Clin. Cancer Res., 8: 2024-2034, 2002..
9.
2003
-
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach.
2023
-
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).
2021
-
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
2021
-
Predicting CAR-T cell Immunotherapy Success through ImmunoPET.
2020
-
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
2020
-
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.
2019
-
Personalized tamoxifen: a step closer but miles to go.
2010
-
Tumor hypoxia imaging.
2006
-
Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study.
2009
-
Computed tomography screening for lung cancer.
2008
-
The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
2006
-
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
2007
-
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
2006
-
Innovations and challenges in renal cancer: consensus statement from the first international conference.
2004
-
Novel agents in the treatment of lung cancer: conference summary statement.
2004
-
On the Precipice of a "Rituximab-Like" Era for T-Cell Lymphomas?.
29.
2023
-
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid)..
29.
2023
-
Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells..
29.
2023
-
Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset..
28.
2022
-
XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL..
28.
2022
-
Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies..
11.
2005
-
Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism..
10.
2004
-
Of peptides and peptidases: the role of cell surface peptidases in cancer..
9.
2003
-
Molecular imaging in oncology: the diagnostic imaging "revolution"..
6.
2000
-
Discodermolide: just another microtubule-stabilizing agent? No! A lesson in synergy..
6.
2000
-
Progresses Toward Precision Medicine in RET-altered Solid Tumors.
2020
-
Radiation-induced Adaptive Response: New Potential for Cancer Treatment.
2020
-
Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.
2019
-
Immunotherapy of Melanoma: Facts and Hopes.
2019
-
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
2018
-
Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
2017
-
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
2017
-
The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
2016
-
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.
2016
-
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
2015
-
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
2014
-
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence.
2014
-
Aggressive variants of castration-resistant prostate cancer.
2014
-
Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
2013
-
Circulating tumor cells as biomarkers in prostate cancer.
2011
-
Prognostic immune markers in non-small cell lung cancer.
2011
-
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.
2010
-
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.
2010
-
Lung cancer in never smokers: clinical epidemiology and environmental risk factors.
2009
-
Lung cancer in never smokers: molecular profiles and therapeutic implications.
2009
-
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
2009
-
Microtubule active agents: beyond the taxane frontier.
2008
-
Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature.
2008
-
Tissue-based research in kidney cancer: current challenges and future directions.
2008
-
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy.
2008
-
The potential of antiangiogenic therapy in non-small cell lung cancer.
2007
-
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
2006
-
Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
2006
-
Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
2006
-
The progress and promise of molecular imaging probes in oncologic drug development.
2005
-
Cell death independent of caspases: a review.
2005
-
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
2005
-
Soft tissue sarcomas of adults: state of the translational science.
2003
-
Ceramide and the induction of apoptosis.
1996
-
Radioimmunotherapy of hematological cancer: problems and progress.
1995
-
The emerging role of paclitaxel in breast cancer therapy.
1995
-
New Means and Challenges in the Targeting of BTK.
2024
-
Facts and Hopes in Immunotherapy of Pancreatic Cancer.
2022
-
Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
2019
-
A Method to Summarize Toxicity in Cancer Randomized Clinical Trials.
2018
-
Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.
2014
-
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
2014
-
"Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation.
2014
-
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
2013
-
The winning formulation: the development of paclitaxel in pancreatic cancer.
2013
-
New strategies in sarcoma therapy: linking biology and novel agents.
2012
-
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas.
2012
-
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
2007
-
Mouse modeling in oncologic preclinical and translational research.
2006
-
Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
2006
-
Epratuzumab: targeting B-cell malignancies through CD22.
2003
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)